Biomarker for epilepsy diagnosis

A biomarker, epilepsy technology, applied in biological testing, disease diagnosis, biomaterial analysis, etc., can solve the method of shortening the period of antiepileptic drug taking, without serum or cerebrospinal fluid prediction, diagnosis, treatment and prognosis evaluation kit products And other issues

Inactive Publication Date: 2018-06-05
PEKING UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinically, the side effects of long-term oral antiepileptic drugs, such as: obesity, mental symptoms, liver and kidney function damage, etc., as well as economic factors are recognized by clinicians. Therefore, the use of antiepileptic drugs should be shortened as much as ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for epilepsy diagnosis
  • Biomarker for epilepsy diagnosis
  • Biomarker for epilepsy diagnosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0031] 1. Sample collection

[0032] There were 6 patients clinically diagnosed as drug-refractory epilepsy (Table 1), all of whom were temporal lobe epilepsy. They all underwent the same surgical treatment: anterior temporal lobe plus hippocampal amygdala resection. Follow-up was carried out after operation. During the follow-up, the 6 patients were all in line with the standard of clinical cure through the verification of EEG and clinical seizures. The peripheral venous blood or arterial blood of the patients was collected according to different time points, the time points were: preoperative, postoperative follow-up for half a year, and postoperative follow-up for one year. 5ml of peripheral blood was drawn each time, centrifuged at 4000rpm / min for 20 minutes, and then the supernatant (serum) was collected and stored at -80°C.

[0033] Table 1. Basic information of clinical samples

[0034]

[0035]

[0036] Case I is the screening experimental sample, and cases II-...

Embodiment approach 2

[0078] Verification experiment based on the above results to expand the sample

[0079] The experimental technical process is the same as the screening experimental technical process ( figure 1 )

[0080] The case numbers of the verification experimental samples are II-VI, and they are cured cases of temporal lobe epilepsy like the screening experimental case I.

[0081] The reagents, proportioning ratio, reaction time, light-heavy labeling and other methods used in the verification experiment are the same as those in the screening experiment.

[0082] Table 3. Sample grouping and labeling methods for verification experiments

[0083] Labeled sample number

Remark (H)

Light (L)

2

II-PRE

II-POST-HALF

3

III-PRE

III-POST-HALF

4

IV-PRE

IV-POST-HALF

5

IV-PRE

IV-POST-ONE

6

V-PRE

V-POST-HALF

7

V-PRE

V-POST-ONE

8

VI-PRE

VI-POST-HALF

9

VI-PRE

VI-POST-ONE ...

Embodiment approach 3

[0091] Kit: a kit for detecting Hemoglobin subunit beta protein or its degradation products in body fluids or tissues such as serum or cerebrospinal fluid, which contains antibodies against Hemoglobin subunit beta protein or its degradation products.

[0092] The steps of using the above kit to detect the Hemoglobin subunit beta protein or its degradation product in the patient's serum: collect the patient's serum according to the method of embodiment 1, react with the antibody of the Hemoglobin subunit beta protein or its degradation product, and effectively detect the Hemoglobin subunit beta protein or its degradation product of the present invention The expression levels of biomarkers can effectively detect whether the subject has epilepsy, assist in the classification and diagnosis of drug-refractory epilepsy, and determine whether the drug can be reduced or discontinued after surgery for drug-resistant epilepsy.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a biomarker or a biodegradation product thereof for epilepsy prediction, diagnosis, treatment and prognosis evaluation. The protein is named as Hemoglobin subunit beta, and theencoding gene of the biomarker is HBB. Particularly, the invention relates to a proteomic screening and detection method for a Hemoglobin subunit beta protein or a biodegradation product thereof. Results of the method show that before and after epilepsy primary lesion resection operation of a patient suffering from epilepsy, the contents of Hemoglobin subunit beta or biodegradation products thereof in serum are remarkably different (as shown in the figure 1 accompanying the abstract). The biomarker protein Hemoglobin subunit beta or the biodegradation product thereof disclosed by the invention has great significances in fields such as epilepsy research, prediction, diagnosis, treatment and prognosis evaluation.

Description

technical field [0001] The invention relates to the field of biomarkers for disease diagnosis and prediction. In particular, the present invention relates to the use of Hemoglobin subunit beta protein and its biodegradation products as biomarkers in epilepsy prediction, diagnosis, treatment and prognosis assessment, as well as proteomics screening and detection methods. It also relates to the application of Hemoglobin subunit beta protein or its biodegradation product in making epilepsy detection kit. Background technique [0002] Epilepsy is a syndrome of acute brain dysfunction caused by the abnormally synchronized discharge of neurons in the brain. According to epidemiological statistics, at present, epilepsy affects about 1% of the world's population, and its incidence rate is second only to neurovascular diseases. According to the latest epidemiology in my country, the incidence of epilepsy in China is 7‰-1%. [0003] Epilepsy has an extremely serious impact on the n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47G01N30/02G01N33/68
CPCC07K14/47G01N30/02G01N33/6893G01N2333/47G01N2800/2857
Inventor 赵旭阳黄卓马维宁孙智明
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap